266 related articles for article (PubMed ID: 27104864)
41. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
Miyashiro D; Sanches JA
Int J Dermatol; 2022 Apr; 61(4):442-454. PubMed ID: 34435672
[TBL] [Abstract][Full Text] [Related]
42. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
[No Abstract] [Full Text] [Related]
43. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
[TBL] [Abstract][Full Text] [Related]
44. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome).
Jones GW; Rosenthal D; Wilson LD
Cancer; 1999 May; 85(9):1985-95. PubMed ID: 10223240
[TBL] [Abstract][Full Text] [Related]
45. CD30
Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
[No Abstract] [Full Text] [Related]
46. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
47. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
[TBL] [Abstract][Full Text] [Related]
48. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].
Wobser M; Goebeler M
Hautarzt; 2019 Oct; 70(10):815-830. PubMed ID: 31511903
[TBL] [Abstract][Full Text] [Related]
49. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
[TBL] [Abstract][Full Text] [Related]
50. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
51. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
52. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.
Scarisbrick JJ; Quaglino P; Prince HM; Papadavid E; Hodak E; Bagot M; Servitje O; Berti E; Ortiz-Romero P; Stadler R; Patsatsi A; Knobler R; Guenova E; Child F; Whittaker S; Nikolaou V; Tomasini C; Amitay I; Prag Naveh H; Ram-Wolff C; Battistella M; Alberti-Violetti S; Stranzenbach R; Gargallo V; Muniesa C; Koletsa T; Jonak C; Porkert S; Mitteldorf C; Estrach T; Combalia A; Marschalko M; Csomor J; Szepesi A; Cozzio A; Dummer R; Pimpinelli N; Grandi V; Beylot-Barry M; Pham-Ledard A; Wobser M; Geissinger E; Wehkamp U; Weichenthal M; Cowan R; Parry E; Harris J; Wachsmuth R; Turner D; Bates A; Healy E; Trautinger F; Latzka J; Yoo J; Vydianath B; Amel-Kashipaz R; Marinos L; Oikonomidi A; Stratigos A; Vignon-Pennamen MD; Battistella M; Climent F; Gonzalez-Barca E; Georgiou E; Senetta R; Zinzani P; Vakeva L; Ranki A; Busschots AM; Hauben E; Bervoets A; Woei-A-Jin FJSH; Matin R; Collins G; Weatherhead S; Frew J; Bayne M; Dunnill G; McKay P; Arumainathan A; Azurdia R; Benstead K; Twigger R; Rieger K; Brown R; Sanches JA; Miyashiro D; Akilov O; McCann S; Sahi H; Damasco FM; Querfeld C; Folkes A; Bur C; Klemke CD; Enz P; Pujol R; Quint K; Geskin L; Hong E; Evison F; Vermeer M; Cerroni L; Kempf W; Kim Y; Willemze R
Br J Dermatol; 2019 Aug; 181(2):350-357. PubMed ID: 30267549
[TBL] [Abstract][Full Text] [Related]
53. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography.
Tsai EY; Taur A; Espinosa L; Quon A; Johnson D; Dick S; Chow S; Advani R; Warnke R; Kohler S; Hoppe RT; Kim YH
Arch Dermatol; 2006 May; 142(5):577-84. PubMed ID: 16702495
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China: A 12-Year Review.
Chen Z; Lin Y; Qin Y; Qu H; Zhang Q; Li Y; Wen Y; Sun J; Tu P; Gao P; Wang Y
JAMA Dermatol; 2023 Oct; 159(10):1059-1067. PubMed ID: 37585188
[TBL] [Abstract][Full Text] [Related]
55. Association of a Proposed New Staging System for Folliculotropic Mycosis Fungoides With Prognostic Variables in a US Cohort.
Charli-Joseph Y; Kashani-Sabet M; McCalmont TH; Kornak J; Allen I; Ai WZ; LeBoit PE; Pincus LB
JAMA Dermatol; 2021 Feb; 157(2):157-165. PubMed ID: 33295938
[TBL] [Abstract][Full Text] [Related]
56. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia: clinical characteristics, temporal relationships, and survival data in a series of 14 patients at Mayo Clinic.
Chang MB; Weaver AL; Brewer JD
Int J Dermatol; 2014 Aug; 53(8):966-70. PubMed ID: 24134412
[TBL] [Abstract][Full Text] [Related]
58. Mycosis Fungoides and Sézary Syndrome: An Update.
Larocca C; Kupper T
Hematol Oncol Clin North Am; 2019 Feb; 33(1):103-120. PubMed ID: 30497668
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome.
Lemchak D; Banerjee S; Digambar SS; Hood BL; Conrads TP; Jedrych J; Geskin L; Akilov OE
Exp Dermatol; 2018 Feb; 27(2):188-190. PubMed ID: 29205518
[TBL] [Abstract][Full Text] [Related]
60. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
